FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Alert on False Positive Lead Tests

FDA alerts health care providers about reports of falsely elevated results associated with ASP Globals RAM Scientific SAFE-T-FILL Micro Capillary Bloo...

latest-news-card-1
Human Drugs

Multiple Violations at Empower Pharma

FDA warns Houston, TX-based Empower Pharma about multiple violations in its production of unapproved and misbranded compounded drugs.

latest-news-card-1
Human Drugs

Norwich Loses Generic Rifaximin Case

The DC federal court throws out Norwichs suit seeking to force FDA to find that Actavis has forfeited its exclusivity for a generic form of rifaximin ...

latest-news-card-1
Human Drugs

FDA Has No Plans to Pull Abortion Pill: Makary

FDA commissioner Martin Makary says there are no current plans to restrict access to the abortion drug mifepristone.

latest-news-card-1
Medical Devices

Abbott Recalls HeartMate Power Units

Abbott recalls its HeartMate Mobile Power Unit to remove the component due to instances where the device experiences a sudden power loss.

Biologics

FDA Seeks Post-Marketing Commitment from Novavax

Novavax says its Covid-19 vaccine BLA is being held up while FDA seeks to conclude a post-marketing commitment from the company.

Medical Devices

CereVasc Gains Breakthrough Status for eShunt

FDA grants CereVasc a breakthrough device designation for its investigational eShunt System and its use in treating communicating hydrocephalus.

latest-news-card-1
FDA General

ESG NextGen is Live: FDA

FDA says its Electronic Submission Gateway Next Generation is live and ready to receive submissions.

latest-news-card-1
Human Drugs

Vanda Criticizes FDA on Tradipitant Hearing Delay

Vanda Pharmaceuticals criticizes FDA for wrongly claiming that recent staff cuts and a new commissioner causes it to delay a company request for a hea...

latest-news-card-1
Human Drugs

Akesos Ivonescimab Meets Endpoint in Lung Cancer

Akeso says its ivonescimab met the primary endpoint in a pivotal Phase 3 trial for the first-line treatment of advanced squamous non-small cell lung c...